Corning Incorporated announced it will receive $103.8 million in additional funding from the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) in partnership with the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense and Army Contracting Command (JPEO-CBRND). The funding will support Corning’s planned manufacturing expansion of advanced, high-quality pharmaceutical glass tubing and vials, helping the health care industry rapidly scale manufacturing to address current and future public health challenges.
“Corning’s pharmaceutical glass packaging has played a critical role in ensuring the safe and on-time delivery of critical medications,” said Brendan Mosher, vice president and general manager, Corning Pharmaceutical Technologies. “Our Valor® Glass and Velocity® Vials are some of the strongest, fastest to fill, and highest-quality pharmaceutical glass vials available. Our products play a critical role in helping to protect patients by improving glass quality, lowering the risk of contamination, and helping to accelerate the delivery of lifesaving treatments.”
Through this planned investment in Corning’s pharmaceutical glass manufacturing capacity, the U.S. government will strengthen the domestic pharmaceutical supply chain by directly addressing manufacturing efficiency constraints. Under the new agreement funded by BARDA, Corning will continue to expand pharmaceutical tubing manufacturing capacity in Vineland, New Jersey, and vial manufacturing capacity in Durham, North Carolina.